The story of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated massive gains, the lapse of its patent opened the floodgates to cheaper alternatives, https://dawudzknp392189.ja-blog.com/42124060/sildenafil-and-big-pharma-a-volatile-bet